Connect with us

Hi, what are you looking for?

Contribution AmericansContribution Americans

Tech News

23andMe is ending its cancer research program and slashing over 200 jobs

An image showing the 23andMe sign
Photo by Justin Sullivan/Getty Images

23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s massive data breach and reverse its plummeting stock price. The genetic testing company also announced that it will shut down its therapeutics business.

Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a result, while “substantially” lowering operating expenses. 23andMe’s therapeutics division, which studied potential cancer treatments using its database of genetic material, will end all clinical trials, as the company considers licensing agreements or asset sales to “maximize” the program’s value.

23andMe has had a turbulent past year, with the…

Continue reading…

You May Also Like

Editor's Pick

On this week’s edition of StockCharts TV‘s StockCharts in Focus, Grayson discusses the most important chart on all of StockCharts – your default ChartStyle! In addition...

Tech News

Image: the Internet Archive The Internet Archive is back online in a read-only state after a cyberattack brought down the digital library and Wayback...

Editor's Pick

When the market is down, you can see which stocks Wall Street may be pumping money into. So on a Monday morning when the...

Editor's Pick

There are times when the price action of a stock is worth analyzing further. This article is a follow-up to last week’s StockCharts Technical...